Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$3.15 -0.3%	$3.12	$2.01 ▼ $5.64	$209.56M	1.61	1.19 million shs	2.15 million shs
ELDN Eledon Pharmaceuticals	$2.69 -2.2%	$3.01	$2.30 ▼ $5.54	$161.08M	-0.17	309,100 shs	7.55 million shs
IMMX Immix Biopharma	$2.17 -3.1%	$2.14	$1.26 ▼ $3.00	$60.49M	0.31	153,976 shs	170,910 shs
MDWD MediWound	$19.26 -0.7%	$19.62	$14.14 ▼ $24.00	$208.16M	0.38	87,119 shs	174,715 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	-0.32%	+1.61%	-1.25%	-4.26%	+34.62%
ELDN Eledon Pharmaceuticals	-2.18%	-1.10%	-14.60%	-19.70%	+5.91%
IMMX Immix Biopharma	-3.13%	-3.13%	+11.28%	+27.65%	-1.36%
MDWD MediWound	-0.67%	+0.89%	-8.63%	+20.75%	+26.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	1.6342 of 5 stars	3.4	1.0	2.7	0.0	0.6
ELDN Eledon Pharmaceuticals	2.7595 of 5 stars	3.5	4.0	2.8	1.7	0.0
IMMX Immix Biopharma	3.6186 of 5 stars	3.5	5.0	2.2	3.3	0.6
MDWD MediWound	1.8141 of 5 stars	3.5	1.0	2.2	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.80	Moderate Buy	$9.88	213.49% Upside
ELDN Eledon Pharmaceuticals	3.00	Buy	$9.00	234.57% Upside
IMMX Immix Biopharma	3.00	Buy	$7.00	222.58% Upside
MDWD MediWound	3.00	Buy	$31.80	65.11% Upside

Current Analyst Ratings Breakdown

Latest IMMX, ELDN, CRDF, and MDWD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/18/2025	ELDN Eledon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$9.00
6/4/2025	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
5/2/2025	MDWD MediWound	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	308.19	N/A	N/A	$1.86 per share	1.69
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$1.98 per share	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$0.48 per share	N/A
MDWD MediWound	$20.22M	10.30	N/A	N/A	$2.89 per share	6.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
ELDN Eledon Pharmaceuticals	-$36.18M	-$2.10	N/A	N/A	N/A	N/A	-79.54%	-41.62%	8/18/2025 (Estimated)
IMMX Immix Biopharma	-$21.61M	-$0.70	N/A	N/A	N/A	N/A	-130.02%	-86.33%	8/11/2025 (Estimated)
MDWD MediWound	-$30.22M	-$2.09	N/A	N/A	N/A	-110.45%	-74.12%	-30.92%	8/13/2025 (Estimated)

Latest IMMX, ELDN, CRDF, and MDWD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million
5/14/2025	Q1 2025	ELDN Eledon Pharmaceuticals	-$0.28	-$0.08	+$0.20	-$0.08	N/A	N/A
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	6.22	6.22
ELDN Eledon Pharmaceuticals	N/A	13.90	13.91
IMMX Immix Biopharma	N/A	1.80	1.80
MDWD MediWound	N/A	2.15	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
ELDN Eledon Pharmaceuticals	56.77%
IMMX Immix Biopharma	11.26%
MDWD MediWound	46.83%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
ELDN Eledon Pharmaceuticals	12.30%
IMMX Immix Biopharma	55.40%
MDWD MediWound	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
ELDN Eledon Pharmaceuticals	10	59.88 million	52.52 million	Optionable
IMMX Immix Biopharma	9	27.88 million	12.43 million	Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable

IMMX, ELDN, CRDF, and MDWD Headlines

Recent News About These Companies

MediWound Ltd. (NASDAQ:MDWD) Given Average Rating of "Buy" by Analysts

June 27 at 4:31 AM | marketbeat.com

MediWound Ltd. (MDWD) latest stock news and headlines - Yahoo Finance

June 26 at 9:06 PM | sg.finance.yahoo.com

MediWound (NASDAQ:MDWD) Shares Pass Above Fifty Day Moving Average - Time to Sell?

June 25 at 4:58 AM | marketbeat.com

MediWound Ltd. (NASDAQ:MDWD) Shares Acquired by Silverberg Bernstein Capital Management LLC

June 3, 2025 | marketbeat.com

Companies Like MediWound (NASDAQ:MDWD) Are In A Position To Invest In Growth

June 2, 2025 | finance.yahoo.com

MediWound (NASDAQ:MDWD) Coverage Initiated at Oppenheimer

June 2, 2025 | marketbeat.com

MediWound’s Q1 2025: Strategic Progress Amid Financial Challenges

May 21, 2025 | tipranks.com

MediWound (MDWD) Q1 2025 Earnings Call Transcript

May 21, 2025 | msn.com

MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript

May 21, 2025 | seekingalpha.com

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

May 21, 2025 | zacks.com

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 21, 2025 | globenewswire.com

MediWound Q1 2025 Earnings Preview

May 20, 2025 | msn.com

MediWound Ltd.: Undervalued High-Growth Potential

May 16, 2025 | seekingalpha.com

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

May 13, 2025 | globenewswire.com

MediWound to Report First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

April 28, 2025 | globenewswire.com

Those who invested in MediWound (NASDAQ:MDWD) five years ago are up 30%

April 17, 2025 | finance.yahoo.com

MediWound reports Q4 EPS (36c), consensus (61c)

March 20, 2025 | markets.businessinsider.com

MediWound files $125M mixed securities shelf

March 20, 2025 | markets.businessinsider.com

Loss-Making MediWound Ltd. (NASDAQ:MDWD) Expected To Breakeven In The Medium-Term

March 20, 2025 | finance.yahoo.com

MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript

March 20, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX, ELDN, CRDF, and MDWD Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$3.15 -0.01 (-0.32%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.20 +0.06 (+1.75%)

As of 06/27/2025 07:56 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Eledon Pharmaceuticals NASDAQ:ELDN

$2.69 -0.06 (-2.18%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.75 +0.06 (+2.23%)

As of 06/27/2025 07:50 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Immix Biopharma NASDAQ:IMMX

$2.17 -0.07 (-3.13%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.17 +0.00 (+0.23%)

As of 06/27/2025 06:43 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

MediWound NASDAQ:MDWD

$19.26 -0.13 (-0.67%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$19.28 +0.02 (+0.10%)

As of 06/27/2025 04:34 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time